Author

V. Vu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

D. Barsyte-Lovejoy· 3 shared M. D. Minden· 2 shared M. M. Szewczyk· 2 shared A. Murison· 1 shared A. Santiago· 1 shared A. Seitova· 1 shared B. Eguzkitza· 1 shared C. Arrowsmith· 1 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Barsyte-Lovejoy

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Patient-Specific Vascularized Tumor Model: Blocking TAM Recruitment with Multispecific Antibodies Targeting CCR2 and CSF-1R

H. T. Nguyen, N. Gurvich, M. R. Gillrie, G. Offeddu, M. Humayun, E. L. Kan, Z. Wan, M. F. Coughlin, C. Zhang, V. Vu, S. W. L. Lee, S.-L. Tan, D. Barbie, J. Hsu, R. D. Kamm

This paper develops a vascularized tumor model to study TAM recruitment and evaluates a multispecific antibody's effect on monocyte migration and TAM repolarization.

bioRxiv · Nov 28, 2023Bioengineering

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations

M. Alqazzaz, G. Luciani, V. Vu, R. M. Machado, M. M. Szewczyk, E. C. Adamson, S. Cheon, C. Arrowsmith, M. D. Minden, D. Barsyte-Lovejoy

This study identifies epigenetic vulnerabilities in AML and MDS/MPN with EZH2 mutations, showing increased sensitivity to EZH2 and EED inhibitors and upregulation of cell death pathways.

bioRxiv · Nov 20, 2023Cancer Biology

Probing the DCAF12 interactions with MAGEA3 and CCT5 C-terminal degrons

G. L. Righetto, Y. Yin, V. Vu, D. Duda, M. Szewczyk, H. Zeng, Y. Li, P. Loppnau, T. Mei, Y.-Y. Li, A. Seitova, J.-F. Brazeau, D. Barsyte-Lovejoy, V. Santhakumar, C. Chaudhry, L. Halabelian

This study characterizes DCAF12 interactions with MAGEA3 and CCT5 degrons using biophysical assays and cryo-EM, revealing key residues for degron recognition and informing PROTAC design.

bioRxiv · Aug 15, 2023 · PreprintBiochemistry

PRMT5 regulates ATF4 transcript splicing and oxidative stress response

M. M. Szewczyk, G. M. Luciani, V. Vu, A. Murison, D. Dilworth, M. Lupien, C. H. Arrowsmith, M. D. Minden, D. Barsyte-Lovejoy

This study shows PRMT5 regulates ATF4 splicing and oxidative stress response in AML, with EVI1-high cells depending on PRMT5 for redox balance.

bioRxiv · Feb 2, 2022Cancer Biology

Design and execution of a Verification, Validation, and Uncertainty Quantification plan for a numerical model of left ventricular flow after LVAD implantation

A. Santiago, C. Butakoff, B. Eguzkitza, R. A. Gray, K. May-Newman, P. Pathmanathan, V. Vu, M. Vazquez

This paper presents a numerical model of the LV-LVAD system and executes a verification, validation, and uncertainty quantification plan to ensure credible predictions of left ventricular flow.

bioRxiv · Nov 11, 2021Bioengineering